4D Molecular Therapeutics (FDMT) Net Cash Flow (2020 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly Net Cash Flow of $12.2 million for Q1 2026, up 177.46% year-over-year from $4.4 million in Q1 2025, and up 4.8% quarter-over-quarter from $11.7 million in Q4 2025.
4D Molecular Therapeutics (FDMT) Net Cash Flow (2020 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Net Cash Flow for 7 consecutive years, with $12.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 177.46% year-over-year to $12.2 million; the TTM figure through Mar 2026 stood at -$61.0 million (up 57.04% YoY), while the FY2025 annual figure was -$89.1 million, up 10.7% from the prior year.
- Net Cash Flow grew to $12.2 million in Q1 2026 per FDMT's latest filing, from $11.7 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $157.7 million in Q2 2023 and bottomed at -$86.5 million in Q2 2024.
- Historically, Net Cash Flow has averaged -$4.7 million across 5 years, with a median of -$5.2 million in 2022.
- Annual changes were most pronounced in 2023 — Net Cash Flow jumped 859.1% — and 2025, when it slumped 1779.37%.
- 4D Molecular Therapeutics' Net Cash Flow stood at -$55.9 million in 2022, then surged by 52.51% to -$26.6 million in 2023, then sank by 43.78% to -$38.2 million in 2024, then soared by 130.59% to $11.7 million in 2025, then increased by 4.8% to $12.2 million in 2026.
- Business Quant data shows FDMT's Net Cash Flow at $12.2 million in Q1 2026, $11.7 million in Q4 2025, and -$28.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - | -2.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.12 Mn |
| Jun 30, 2026 | -2.12 Mn |
| Mar 31, 2026 | 12.25 Mn |
| Mar 31, 2026 | 12.25 Mn |
| Dec 31, 2025 | 11.69 Mn |
| Dec 31, 2025 | 11.69 Mn |
| Sep 30, 2025 | -28.60 Mn |
| Sep 30, 2025 | -28.60 Mn |
| Jun 30, 2025 | -56.37 Mn |
| Jun 30, 2025 | -56.37 Mn |
| Mar 31, 2025 | -15.81 Mn |
| Mar 31, 2025 | -15.81 Mn |
| Dec 31, 2024 | -38.20 Mn |
| Dec 31, 2024 | -38.20 Mn |
| Sep 30, 2024 | -1.52 Mn |
| Sep 30, 2024 | -1.52 Mn |
| Jun 30, 2024 | -86.53 Mn |
| Jun 30, 2024 | -86.53 Mn |
| Mar 31, 2024 | 26.49 Mn |
| Mar 31, 2024 | 26.49 Mn |